DANAZOL: AN "OLD-FASHIONED" DRUG FOR A CURRENT PROBLEM IN LOWER-RISK MYELODYSPLASTIC SYNDROMES

被引：0
|
作者：
Riva, M. [1 ]
Crucitti, L. [1 ]
Ravano, E. [1 ]
Nichelatti, M. [1 ]
Reda, G. [2 ]
Cassin, R. [2 ]
Frangi, C. [1 ]
Cairoli, R. [1 ]
Molteni, A. [3 ]
机构：
[1] ASST Grande Osped Metropolitano Niguarda, Milan, Italy
[2] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy
[3] ASST Cremona, Cremona, Italy
来源：
HAEMATOLOGICA | 2019年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
C073
引用
收藏
页码：43 / 43
页数：1
相关论文
共 50 条
  • [21] EASIX for prediction of survival in lower-risk myelodysplastic syndromes
    Merz, Almuth
    Germing, Ulrich
    Kobbe, Guido
    Kaivers, Jennifer
    Jauch, Anna
    Radujkovic, Aleksandar
    Hummel, Manuela
    Benner, Axel
    Merz, Maximilian
    Dreger, Peter
    Luft, Thomas
    [J]. BLOOD CANCER JOURNAL, 2019, 9 (11)
  • [22] Focus on Anemia in Managing Lower-Risk Myelodysplastic Syndromes
    Chung, Clement
    [J]. US PHARMACIST, 2021, 46 (09) : 39 - 44
  • [23] Management of Lower-Risk Myelodysplastic Syndromes:The Art and Evidence
    Rami S. Komrokji
    Mikkael A. Sekeres
    Alan F. List
    [J]. Current Hematologic Malignancy Reports, 2011, 6 : 145 - 153
  • [24] How we treat lower-risk myelodysplastic syndromes
    Fenaux, Pierre
    Ades, Lionel
    [J]. BLOOD, 2013, 121 (21) : 4280 - 4286
  • [25] Extended Abstract: Treatment of Lower-Risk Myelodysplastic Syndromes
    Steensma, David P.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S17 - S18
  • [26] Therapeutic Modalities for Patients with Lower-Risk Myelodysplastic Syndromes: Current Options and Future Directions
    Shyamala C. Navada
    Lewis R. Silverman
    [J]. Current Hematologic Malignancy Reports, 2011, 6 : 5 - 12
  • [27] Therapeutic Modalities for Patients with Lower-Risk Myelodysplastic Syndromes: Current Options and Future Directions
    Navada, Shyamala C.
    Silverman, Lewis R.
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (01) : 5 - 12
  • [28] Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia
    Cappellini, Maria Domenica
    Taher, Ali T.
    Verma, Amit
    Shah, Farrukh
    Hermine, Olivier
    [J]. BLOOD REVIEWS, 2023, 59
  • [29] Prognostic significance of hyperfibrinogenemia in patients with lower-risk myelodysplastic syndromes
    Ogura, Shinji
    Yonei, Shoichiro
    Tanigawa, Tomohiko
    Akimoto, Masahiro
    Sakurai, Aki
    Fujita, Yuriko
    Ito, Chisako
    Aisa, Yoshinobu
    Nakazato, Tomonori
    [J]. ANNALS OF HEMATOLOGY, 2020, 99 (01) : 189 - 191
  • [30] Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms
    Badar, Talha
    Madanat, Yazan F.
    Zeidan, Amer M.
    [J]. FUTURE ONCOLOGY, 2023, 19 (27) : 1877 - 1889
12345